{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:26:55Z","timestamp":1789914415512,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1053\/j.ajkd.2016.12.013","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T03:49:07Z","timestamp":1488167347000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome"],"prefix":"10.1053","volume":"70","author":[{"given":"Luca","family":"Perico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo","family":"Schieppati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Longaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.ajkd.2016.12.013_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11864-016-0421-5","article-title":"The promise of molecularly targeted and immunotherapy for advanced melanoma","volume":"17","author":"Margolin","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"6892","key":"10.1053\/j.ajkd.2016.12.013_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.ajkd.2016.12.013_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.critrevonc.2015.08.021","article-title":"Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma","volume":"96","author":"Carlino","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7315","key":"10.1053\/j.ajkd.2016.12.013_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1053\/j.ajkd.2016.12.013_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2016.12.013_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9829","key":"10.1053\/j.ajkd.2016.12.013_bib7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1053\/j.ajkd.2016.12.013_bib8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9992","key":"10.1053\/j.ajkd.2016.12.013_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600\u00a0BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.ajkd.2016.12.013_bib10","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.28709","article-title":"Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients","volume":"120","author":"Launay-Vacher","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.ajkd.2016.12.013_bib11","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.013_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14740338.2016.1164139","article-title":"BRAF inhibitors - do we need to worry about kidney injury?","volume":"15","author":"Wanchoo","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1053\/j.ajkd.2016.12.013_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.ajkd.2016.12.013_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.ajkd.2016.12.013_bib15","first-page":"143","article-title":"Glomerular diseases and cancer: evaluation of underlying malignancy","volume":"29","author":"Pani","year":"2016","journal-title":"J\u00a0Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.013_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.annder.2010.10.024","article-title":"[Membranous glomerulonephritis as a paraneoplastic manifestation of melanoma]","volume":"138","author":"Sultan-Bichat","year":"2011","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"10.1053\/j.ajkd.2016.12.013_bib17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/0886022X.2010.502278","article-title":"Renal glomerular alterations in patients with cancer: a clinical and immunohistochemical autopsy study","volume":"32","author":"Faria","year":"2010","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.013_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.08.003","article-title":"Paraneoplastic glomerular diseases and malignancies","volume":"70","author":"Bacchetta","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.013_bib19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.03770412","article-title":"Onco-nephrology: glomerular diseases with cancer","volume":"7","author":"Cambier","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.013_bib20","series-title":"Brenner & Rector's The Kidney","first-page":"1265","article-title":"Diabetic nephropathy","author":"Parving","year":"2007"},{"key":"10.1053\/j.ajkd.2016.12.013_bib21","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1038\/sj.ki.5002384","article-title":"Podocyte biology in\u00a0diabetic nephropathy","volume":"106","author":"Li","year":"2007","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.013_bib22","doi-asserted-by":"crossref","first-page":"F93","DOI":"10.1152\/ajprenal.00345.2007","article-title":"Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3","volume":"294","author":"Chaib","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.013_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/ng1918","article-title":"Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible","volume":"38","author":"Hinkes","year":"2006","journal-title":"Nat Genet"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.013_bib24","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1681\/ASN.2014040405","article-title":"Nephrin preserves podocyte viability and glomerular structure and function in adult kidneys","volume":"26","author":"Li","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2016.12.013_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1097-2765(00)80057-X","article-title":"Positionally cloned gene for a novel glomerular protein\u2013nephrin\u2013is mutated in congenital nephrotic syndrome","volume":"1","author":"Kestila","year":"1998","journal-title":"Mol Cell"},{"issue":"25","key":"10.1053\/j.ajkd.2016.12.013_bib26","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1073\/pnas.0611308104","article-title":"IQGAP1 modulates activation of B-Raf","volume":"104","author":"Ren","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.013_bib27","doi-asserted-by":"crossref","first-page":"e37695","DOI":"10.1371\/journal.pone.0037695","article-title":"IQGAP1 interacts with components of the slit diaphragm complex in podocytes and is involved in podocyte migration and permeability in\u00a0vitro","volume":"7","author":"Rigothier","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.ajkd.2016.12.013_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0092-8674(93)90411-I","article-title":"Extracellular signals and reversible protein phosphorylation: what to Mek of it all","volume":"74","author":"Crews","year":"1993","journal-title":"Cell"},{"issue":"1-2","key":"10.1053\/j.ajkd.2016.12.013_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0248-4900(01)01125-X","article-title":"The Raf\/MEK\/ERK pathway: new concepts of activation","volume":"93","author":"Peyssonnaux","year":"2001","journal-title":"Biol Cell"},{"issue":"3","key":"10.1053\/j.ajkd.2016.12.013_bib30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403269","article-title":"Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis","volume":"18","author":"Giuliani","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.013_bib31","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/ndt\/gfq200","article-title":"Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans","volume":"25","author":"Hohenstein","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.013_bib32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.013_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1053\/j.ajkd.2016.12.013_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","article-title":"Inhibition of the VEGF signalling pathway and glomerular disorders","volume":"30","author":"Ollero","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2016.12.013_bib35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy","volume":"74","author":"Stokes","year":"2008","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2016.12.013_bib36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.013_bib37","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1345\/aph.1R160","article-title":"Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor","volume":"46","author":"Turan","year":"2012","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617301130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617301130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:57:50Z","timestamp":1759460270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617301130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0272638617301130"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}